公开(公告)号：US20130345805A1

公开(公告)日：2013-12-26

申请号：US13897249

申请日：2013-05-17

申请人： CARDIAC PACEMAKERS, INC. ,  CRITICAL CARE DIAGNOSTICS, INC.

发明人： James V. SNIDER ,  Timothy Edward MEYER ,  Craig Michael STOLEN ,  Robert W. GERWIEN

IPC分类号： G01N33/68

CPC分类号： G01N33/6887 ,  A61B5/7275 ,  A61N1/3627 ,  A61N1/3956 ,  G01N33/6893 ,  G01N2333/7155 ,  G01N2800/325 ,  G01N2800/326 ,  G01N2800/50

摘要： Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.

摘要翻译： 本文提供的方法包括（i）确定来自受试者的生物样品中可溶性ST2的水平，（i）将生物样品中的可溶性ST2水平与可溶性ST2的参考水平（例如，可溶性水平 ST2），以及（iii）选择，植入，替换或重新编程植入的心脏装置，例如ICD，CRT或CRT-D装置，用于具有升高的可溶性水平的受试者 生物样品中的ST2与可溶性ST2的参考水平相比较，或选择参与或主动参与减轻心室性快速性心律失常（VTA）事件风险的治疗的临床研究的受试者。 还提供了评估受试者中VTA事件风险的方法。 还提供了用于执行任何这些方法的套件。